(Q35974039)

11 August 2017

1 reference

title

Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use? (English)

1 reference

relapsing-remitting multiple sclerosis

11 August 2017

main subject

1 reference

Oscar Fernández

1

1 reference

11 August 2017

language of work or name

1 reference

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

18

1 reference

11 August 2017

issue

15

1 reference

11 August 2017

page(s)

1057-1070

1 reference

The molecular cell biology of interferon-gamma and its receptor

11 August 2017

cites work

1 reference

12 December 2020

Immunoregulation and blocking antibodies induced by interferon beta treatment in MS

1 reference

12 December 2020

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

12 December 2020

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

12 December 2020

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

1 reference

12 December 2020

Natural interferon-beta treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study

1 reference

12 December 2020

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Three-dimensional structure of recombinant human interferon-gamma

1 reference

12 December 2020

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Virus interference. I. The interferon

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

12 December 2020

Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases

1 reference

12 December 2020

Studies of Interferon Production and Natural Killing by Lymphocytes from Multiple Sclerosis Patients

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial

1 reference

12 December 2020

The Purification and Manufacture of Human Interferons / Sidney Pestka. - (1983)

1 reference

12 December 2020

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

12 December 2020

Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.

1 reference

12 December 2020

IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis

1 reference

12 December 2020

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Effect of rat and beta-human interferons on hyperacute experimental allergic encephalomyelitis in rats

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

Immunomodulatory effects of interferon beta-1a in multiple sclerosis

1 reference

12 December 2020

The use of quality of life measures in multiple sclerosis research.

1 reference

12 December 2020

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

12 December 2020

Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies (NAB)

1 reference

12 December 2020

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

12 December 2020

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

1 reference

12 December 2020

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Interferon responses of leukocytes in multiple sclerosis

1 reference

12 December 2020

Interferon in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Clinical benefits of interferon beta-1a in relapsing-remitting MS: a phase IV study

1 reference

12 December 2020

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain

1 reference

12 December 2020

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

1 reference

12 December 2020

Pretreatment of astrocytes with interferon-alpha/beta prevents neuronal mitochondrial respiratory chain damage.

1 reference

12 December 2020

The clinical impact of interferon beta antibodies in relapsing-remitting MS.

1 reference

12 December 2020

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by interferon

1 reference

12 December 2020

Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients

1 reference

12 December 2020

Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up

1 reference

12 December 2020

Differentiation of multiple sclerosis subtypes: implications for treatment

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

12 December 2020

Interferons and their actions

1 reference

12 December 2020

Beta-interferon and multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses

1 reference

12 December 2020

Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta

1 reference

12 December 2020

Interferon beta augments suppressor cell function in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

12 December 2020

Treatment with interferon beta-1b improves quality of life in multiple sclerosis.

1 reference

12 December 2020

Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer.

1 reference

12 December 2020

Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre

1 reference

12 December 2020

Immunological effects of in vivo interferon-beta1b treatment in ten patients with multiple sclerosis: a 1-year follow-up

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Interferon beta treatment in relapsing-remitting multiple sclerosis. A review

1 reference

12 December 2020

Considerations in the treatment of relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

1 reference

12 December 2020

Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-beta

1 reference

12 December 2020

Long-term interferon-beta treatment for multiple sclerosis

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis: a systematic review

1 reference

12 December 2020

[Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial]

1 reference

12 December 2020

Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes

1 reference

12 December 2020

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

12 December 2020

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis

1 reference

12 December 2020

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

12 December 2020

10.2165/00023210-200418150-00002

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nqzhtp6v25cf3iru3tzpnpfxtm

30 July 2022

mapped directly with Wikidata item

Dimensions Publication ID

1014941666

0 references

Fatcat ID

release_nqzhtp6v25cf3iru3tzpnpfxtm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nqzhtp6v25cf3iru3tzpnpfxtm

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/nqzhtp6v25cf3iru3tzpnpfxtm

1 reference

30 July 2022